Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

698
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

524
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
524
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
Disorders of Hemostasis01:24

Disorders of Hemostasis

911
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
911
Structure and Function of Platelets01:18

Structure and Function of Platelets

1.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.2K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

5.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world performance of myositis antibody panels: a single-centre experience.

Rheumatology (Oxford, England)·2026
Same author

Executive Summary: The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026
Same author

The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026
Same author

Prevalence and prognostic value of activated protein C resistance and anti-protein C antibodies in patients with aPLs: an APS ACTION Registry study.

Rheumatology (Oxford, England)·2026
Same author

Correction: Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohorts.

Frontiers in immunology·2026
Same author

Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohorts.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jul 4, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

378

Platelets and Thrombotic Antiphospholipid Syndrome.

Ibrahim Tohidi-Esfahani1,2, Prabal Mittal3,4, David Isenberg5

  • 1Haematology Department, Concord Repatriation General Hospital, Sydney, NSW 2139, Australia.

Journal of Clinical Medicine
|February 10, 2024
PubMed
Summary

Antiphospholipid antibody syndrome (APS) involves thrombosis due to antiphospholipid antibodies (aPL). Platelet hyperreactivity is key, yet antiplatelet therapies are limited, necessitating better treatment strategies.

Keywords:
antiphospholipid antibodiesantiphospholipid syndromeantiplateletsplateletsthrombosis

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.7K
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

554

Related Experiment Videos

Last Updated: Jul 4, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

378
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.7K
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

554

Area of Science:

  • Immunology
  • Hematology
  • Vascular Biology

Background:

  • Antiphospholipid antibody syndrome (APS) is an autoimmune disorder causing recurrent thrombosis.
  • Standard care (VKA) is often insufficient, leading to significant morbidity.
  • Platelet hyperreactivity is a central mechanism in APS pathophysiology.

Purpose of the Study:

  • To review evidence on platelet activation in APS.
  • To explore the role of platelets in APS-related thrombosis.
  • To assess current antiplatelet therapy efficacy and future directions.

Main Methods:

  • Literature review of clinical outcomes studies.
  • Analysis of pathophysiological mechanisms of platelet activation in APS.
  • Examination of existing data on antiplatelet therapies.

Main Results:

  • Platelet activation and aggregation are common endpoints in APS thrombosis pathways.
  • Excessive platelet reactivity is clearly demonstrated in APS.
  • Current antiplatelet therapies have a limited role, mainly low-dose aspirin for specific cases.

Conclusions:

  • Platelet hyperreactivity is a critical factor in APS-associated thrombosis.
  • Targeting platelet pathways may offer new therapeutic avenues.
  • Further research is needed to optimize antiplatelet strategies for APS.